NCATS Opens Repurposing Project With 58 Compounds, 17 From Pfizer
Executive Summary
The National Institutes of Health’s National Center for Accelerating Translational Science has opened the pilot round of its compound repurposing effort with 58 drug candidates that will be made available to academic researchers. Half of the 58 have failed in previous studies for neurological indications, a recognized trouble spot for drug development.
You may also be interested in...
AstraZeneca Has Stake In Three Of Nine NCATS Research Projects
Nine NIH National Center for Advancing Translational Sciences research projects involving repurposed investigational drugs will be funded with a total of $12.7 million and cover eight disease areas. In addition to AstraZeneca, compounds provided by Pfizer, Sanofi, Lilly and Janssen will be studied.
NIH Royalties For Pfizer, AstraZeneca, Lilly Drugs Remain Open Question In Repurposing Initiative
With collaborative research agreement templates that include many of the details for a licensing agreement, royalties will be the major issue to be resolved if researchers develop new IP for one of the firm’s abandoned compounds.
Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says
Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.